ATHA – athira pharma, inc. (US:NASDAQ)
Stock Stats
News
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates [Yahoo! Finance]
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $5.00.
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Form SC 13G/A Athira Pharma, Inc. Filed by: BAKER BROS. ADVISORS LP
Form 10-Q Athira Pharma, Inc. For: Sep 30
Form 8-K Athira Pharma, Inc. For: Nov 07
Form SC 13G Athira Pharma, Inc. Filed by: BML Investment Partners, L.P.
Form SC 13D/A Athira Pharma, Inc. Filed by: PERCEPTIVE ADVISORS LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.